Endophthalmitis After Anti-VEGF Injections

Ophthalmology

Volumn 116, Issue 6, 2009, Pages

  Klein, Kathryn S ^a   Walsh, Mark K ^a   Hassan, Tarek S ^a   Halperin, Lawrence S ^a   Castellarin, Alessandro A ^a   Roth, Daniel ^a   Driscoll, Sarah ^a   Prenner, Jonathan L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CEFTAZIDIME; CIPROFLOXACIN; MOXIFLOXACIN; PEGAPTANIB; POVIDONE IODINE; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; VANCOMYCIN; VASCULOTROPIN ANTIBODY;

ENDOPHTHALMITIS; HEALTH SURVEY; HUMAN; LETTER; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; PHYSICIAN; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; VITRECTOMY;

EID: 66049110107     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2009.02.031     Document Type: Letter

References (5)

1. Jager R.D., Aiello L.P., Patel S.C., and Cunningham Jr. E.T. Risks of intravitreous injection: a comprehensive review. Retina 24 (2004) 676-698
2. Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
3. Fintak D.R., Shah G.K., Blinder K.J., et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 28 (2008) 1395-1399
4. Pilli S., Kotsolis A., Spaide R.F., et al. Endophthalmitis associated with intravitreal anti-vascular growth factor therapy injections in an office setting. Am J Ophthalmol 145 (2008) 879-882
5. Mason III J.O., White M.F., Feist R.M., et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 28 (2008) 564-567